Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Bacteria or actinomycetales
Reexamination Certificate
2002-03-05
2004-12-28
Marx, Irene (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Bacteria or actinomycetales
C435S252900
Reexamination Certificate
active
06835376
ABSTRACT:
The present invention pertains to novel microorganisms of the genus
Lactobacillus
, that are useful in preventing diarrhoea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestable support and to a composition containing the same.
Organisms that produce lactic acid as a major metabolic component have been known for a long time. These bacteria may be found in milk or in milk processing factories, respectively, living or decaying plants but also in the intestine of man and animals. These microorganisms, summarized under the term “lactic acid bacteria”, represent a rather inhomogeneous group and comprise e.g. the genera
Lactococcus, Lactobacillus, Streptococcus, Bifidobacterium, Pediococcus
etc.
Lactic acid bacteria have been utilized as fermenting agents for the preservation of food taking benefit of a low pH and the action of fermentation products generated during the fermentative activity thereof to inhibit the growth of spoilage bacteria. To this end, lactic acid bacteria have been used for preparing a variety of different foodstuff such as cheese, yogurt and other fermented diary products from milk.
Quite recently lactic acid bacteria have attracted a great deal of attention in that some strains have been found to exhibit valuable properties to man and animals upon ingestion. In particular, specific strains of the genus
Lactobacillus
or
Bifidobacterium
have been found to be able to colonize the intestinal mucosa and to assist in the maintenance of the well-being of man and animal.
In this respect, EP 0 768 375 discloses specific strains of the genus
Bifidobacterium
, that are capable to become implanted in the intestinal flora and may adhere to intestinal cells. These
Bifidobacteria
are reported to assist in immunomodulation, being capable to competitively exclude adhesion of pathogenic bacteria to intestinal cells, thus assisting in the maintenance of the individual's health.
During the last few years research has also focused on the potential use of lactic acid bacteria as probiotic agents. Probiotics are considered to be viable microbial preparations which promote the individual's health by preserving the natural microflora in the intestine. A microbial preparation may be commonly accepted as a probiotic in case the effectual microbes thereof and their mode of action are known. Probiotics are deemed to attach to the intestine's mucosa, colonize the intestinal tract and likewise prevent attachment of harmful microorganisms thereon. A crucial prerequisite for their action resides in that they have to reach the gut's mucosa in a proper and viable form and do not get destroyed in the upper part of the gastrointestinal tract, especially by the influence of the low pH prevailing in the stomach.
In this respect, WO 97/00078 discloses a specific strain, termed
Lactobacillus
GG (ATCC 53103), as such a probiotic. The microorganism is particularly employed in a method of preventing or treating food induced hypersensitivity reactions in that it is administered to a recipient together with a food material that has been subjected to a hydrolysis treatment with pepsin and/or trypsin. The
Lactobacillus
strain selected is described as exhibiting adhesive and colonizing properties and showing a protease enzyme system, so that the protein material contained in the foodstuff to be administered is further hydrolyzed by means of proteases secreted by the specific
Lactobacillus
strain. The method discussed in this document shall eventually result in the uptake of protein material by the gut that does not show a substantial amount of allergenic material anymore.
Further, in EP 0 577 903 reference is made to the use of such lactic acid bacteria having the ability of replacing
Heliobacter pylori
, the acknowledged cause for the development of ulcer, in the preparation of a support intended for the therapeutic or prophylactic treatment of an ulcer associated with the action of
Heliobacter pylori.
In knowledge of the valuable properties particular strains of lactic acid bacteria may provide, there is a desire in the art for additional lactic acid bacterial strains that are beneficial to the well being of man and/or animal.
Consequently, a problem of the present invention is to provide additional bacterial strains that exhibit new properties beneficial for man and/or animals.
The above problem has been solved by providing novel microorganisms, namely lactic acid bacteria, belonging to the genus
Lactobacillus
having the capability of preventing colonization of the intestine with pathogenic bacteria causing diarrhoea.
According to a preferred embodiment the
Lactobacillus
strain is capable of adhering to the intestinal mucosa of mammal and may grow in the presence of up to 0.4% bile salts.
Yet, according to another preferred embodiment the lactic acid bacterium is selected from the group consisting of
Lactobacillus rhamnosus
or
Lactobacillus paracasei
, preferably
Lactobacillus paracasei
, and is more preferably
Lactobacillus paracasei
CNCM I-2116.
The microorganisms of the present invention have been shown to exhibit inter alia the following properties: they are gram positive, catalase negative, NH
3
form arginine negative and CO
2
production negative, they produce L(+) lactic acid, are capable to grow in the presence of bile salts in a concentration of up to about 0.4% and may essentially prevent colonization of intestinal cells by bacteria bringing about diarrhoea, such as pathogenic
E. coli
, e.g. enteropathogenic
E.coli
(EPEC), or
salmonella
, e.g.
salmonella typhimurium.
The novel microorganisms may be used for the preparation of a variety of ingestable support materials, such as e.g. milk, yogurt, curd, fermented milks, milk based fermented products, fermented cereal based products, milk based powders, infant formulae and may be included in the support in an amount of from about 10
5
cfu/g to about 10
11
cfu/g. For the purpose of the present invention the abbreviation cfu shall designate a “colony forming unit” that is defined as number of bacterial cells as revealed by microbiological counts on agar plates.
The present invention also provides a food or a pharmaceutical composition containing at least one of the
Lactobacillus
strains having the above traits and/or containing a supernatant of a culture, in which the microorganisms have been grown or a fraction thereof, respectively.
For preparing a food composition according to the present invention at least one of the
Lactobacillus
strains of the present invention is incorporated in a suitable support, in an amount of from about 10
5
cfu/g to about 10
11
cfu/g, preferably from about 10
6
cfu/g to about 10
10
cfu/g, more preferably from about 10
7
cfu/g to about 10
9
cfu/g.
In case of a pharmaceutical preparation the product may be prepared in forms of tablets, liquid bacterial suspensions, dried oral supplements, wet oral supplements, dry tube feeding or a wet tube feeding with the amount of
Lactobacillus
strains to be incorporated therein being in the range of up to about 10
12
cfu/g, preferably from about 10
7
cfu/g to about 10
11
cfu/g, more preferably from about 10
7
cfu/g to about 10
10
cfu/g.
The activity of the novel microorganisms in the individual's intestine is naturally dose dependent. That is, the more the novel microorganisms are incorporated by means of ingesting the above food material or the pharmaceutical composition the higher the protective and/or curing activity of the microorganisms. Since the novel microorganisms are not detrimental to mankind and animals and have eventually been isolated from baby feces a high amount thereof may be incorporated so that essentially a high proportion of the individual's intestine will be colonized by the novel microorganisms.
Yet, according to another preferred embodiment the supernatant of a culture of a
Lactobacillus
strain of the present invention may be used for preparing one of the above ingestable s
Neeser Jean-Richard
Reniero Roberto
Servin Alain
Bell Boyd & Lloyd LLC
Marx Irene
Nestec S.A.
LandOfFree
Lactobacillus paracasei strain for preventing diarrhea... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactobacillus paracasei strain for preventing diarrhea..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactobacillus paracasei strain for preventing diarrhea... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3291860